These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 27930366)

  • 21. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
    Afifi S; Michael A; Lesokhin A
    Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.
    Nijhof IS; Lammerts van Bueren JJ; van Kessel B; Andre P; Morel Y; Lokhorst HM; van de Donk NW; Parren PW; Mutis T
    Haematologica; 2015 Feb; 100(2):263-8. PubMed ID: 25510242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The safety of daratumumab for the treatment of multiple myeloma.
    Cejalvo MJ; Ribas P; de la Rubia J
    Expert Opin Drug Saf; 2017 Jun; 16(6):753-760. PubMed ID: 28490215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.
    Moreau P; van de Donk NW; San Miguel J; Lokhorst H; Nahi H; Ben-Yehuda D; Cavo M; Cook G; Delforge M; Einsele H; Zweegman S; Ludwig H; Driessen C; Palumbo A; Facon T; Plesner T; Dimopoulos M; Sondergeld P; Sonneveld P; Mateos MV
    Drugs; 2016 May; 76(8):853-67. PubMed ID: 27113582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Electrophoretic research on the plasmatic and urinary proteins in multiple myeloma].
    GASTALDI F; RODARI T; CERESA G
    Rass Fisiopatol Clin Ter; 1961 Jul; 33():551-72. PubMed ID: 13897203
    [No Abstract]   [Full Text] [Related]  

  • 26. Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.
    Blair HA
    Drugs; 2017 Dec; 77(18):2013-2024. PubMed ID: 29127588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunochemical study of serum and urine proteins.
    Shulman G
    S Afr Med J; 1972 Jun; 46(25):851. PubMed ID: 5076079
    [No Abstract]   [Full Text] [Related]  

  • 28. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
    Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J
    Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Daratumumab: monoclonal antibody therapy to treat multiple myeloma.
    Xia C; Ribeiro M; Scott S; Lonial S
    Drugs Today (Barc); 2016 Oct; 52(10):551-560. PubMed ID: 27910963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A case of myeloma with the findings of 3 paraproteins in the serum and with Bence Jones proteinuria].
    Korínek J; Libánský J
    Vnitr Lek; 1968 Jul; 14(7):702-8. PubMed ID: 5696407
    [No Abstract]   [Full Text] [Related]  

  • 31. Decreasing M spike with increasing tumor burden in multiple myeloma.
    Bouvet JP
    Arch Intern Med; 1982 Jun; 142(6):1240-1. PubMed ID: 7092438
    [No Abstract]   [Full Text] [Related]  

  • 32. Symposium. Myeloma. h. Specificities of gamma-A myeloma proteins.
    Tominaga K
    Nihon Ketsueki Gakkai Zasshi; 1970 Feb; 33(1):85-6. PubMed ID: 5530152
    [No Abstract]   [Full Text] [Related]  

  • 33. Loss of CD38 Expression in Relapsed Refractory Multiple Myeloma.
    Ise M; Matsubayashi K; Tsujimura H; Kumagai K
    Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):e59-64. PubMed ID: 26997107
    [No Abstract]   [Full Text] [Related]  

  • 34. Daratumumab: First Global Approval.
    McKeage K
    Drugs; 2016 Feb; 76(2):275-81. PubMed ID: 26729183
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonsecretory multiple myeloma with amyloidosis. A case report and review of the literature.
    Gafumbegete E; Richter S; Jonas L; Nizze H; Makovitzky J
    Virchows Arch; 2004 Nov; 445(5):531-6. PubMed ID: 15517373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.
    Lokhorst HM; Plesner T; Laubach JP; Nahi H; Gimsing P; Hansson M; Minnema MC; Lassen U; Krejcik J; Palumbo A; van de Donk NW; Ahmadi T; Khan I; Uhlar CM; Wang J; Sasser AK; Losic N; Lisby S; Basse L; Brun N; Richardson PG
    N Engl J Med; 2015 Sep; 373(13):1207-19. PubMed ID: 26308596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigation into the interference of the monoclonal antibody daratumumab on the free light chain assay.
    Rosenberg AS; Bainbridge S; Pahwa R; Jialal I
    Clin Biochem; 2016 Oct; 49(15):1202-1204. PubMed ID: 27475249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple Myeloma: The Case of the Disappearing Band.
    Mamone L; Jones J; Liu S; Li Y; Goldsmith B; Khan AI
    Lab Med; 2017 Dec; 49(1):87-91. PubMed ID: 29309675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Electrophoretic behavior of blood and urine proteins in several cases of plasmocytoma].
    CAGLI V; MANGIONE A
    Policlinico Med; 1956; 63(2):69-84. PubMed ID: 13335522
    [No Abstract]   [Full Text] [Related]  

  • 40. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
    de Weers M; Tai YT; van der Veer MS; Bakker JM; Vink T; Jacobs DC; Oomen LA; Peipp M; Valerius T; Slootstra JW; Mutis T; Bleeker WK; Anderson KC; Lokhorst HM; van de Winkel JG; Parren PW
    J Immunol; 2011 Feb; 186(3):1840-8. PubMed ID: 21187443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.